<code id='7059104624'></code><style id='7059104624'></style>
    • <acronym id='7059104624'></acronym>
      <center id='7059104624'><center id='7059104624'><tfoot id='7059104624'></tfoot></center><abbr id='7059104624'><dir id='7059104624'><tfoot id='7059104624'></tfoot><noframes id='7059104624'>

    • <optgroup id='7059104624'><strike id='7059104624'><sup id='7059104624'></sup></strike><code id='7059104624'></code></optgroup>
        1. <b id='7059104624'><label id='7059104624'><select id='7059104624'><dt id='7059104624'><span id='7059104624'></span></dt></select></label></b><u id='7059104624'></u>
          <i id='7059104624'><strike id='7059104624'><tt id='7059104624'><pre id='7059104624'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:23943
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more
          ProMED sees offers of support, but its future remains unclear
          ProMED sees offers of support, but its future remains unclear

          ProMEDmapScreengrabviaProMEDWithitsfutureindoubt,ProMED,thefinanciallystrappedinfectiousdiseasessurv

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          CDC advisory panel says seniors 'may' get RSV vaccine

          Scanningelectronmicrographofhumanrespiratorysyncytialvirus.NIAIDApanelofexperts thatadvisestheCenter